
"We work to achieve beyond expectations, for every patient and every cancer."
Where I see patients (1)
My reviews
Selected research
-
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
Hepatology (Baltimore, Md.)
-
Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets.
Cancer discovery
-
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Journal of hepatology
5.0